Arcellx and Kite Reveal an Extended Collaboration Within Their Strategic Partnership

Arcellx, Inc and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, initially disclosed in December 2022. In this development, Kite has opted to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, designed for multiple myeloma, with a focus on BCMA. Furthermore, the collaboration scope has widened to include lymphomas for Arcellx's CART-ddBCMA.

Arcellx, expressed enthusiasm about the rapid progress of the partnership and the potential of their innovative synthetic binder, the D-Domain, in creating a new category of CAR T therapies. The deepened collaboration involves Kite's investment in ACLX-001 and increased support for CART-ddBCMA, aiming to extend Arcellx's cash position until 2027.

Kite, highlighted the positive momentum of the CART-ddBCMA program and the extension of the collaboration into areas of significant unmet medical need. Kite's increased engagement aims to advance CART-ddBCMA, strengthen the multiple myeloma pipeline, and explore possibilities in lymphoma.

Arcellx will receive a $200 million equity investment, extending its financial runway. Gilead's estimated ownership in Arcellx will be 13%. The transaction includes an $85 million upfront non-dilutive cash payment, potential milestone payments, and is expected to close by the end of 2023, pending regulatory approvals.

The collaboration between Arcellx and Kite is centered on co-developing and co-commercializing CART-ddBCMA for relapsed or refractory multiple myeloma. The asset utilizes the D-Domain to enhance target specificity and binding affinity. Kite will lead commercialization efforts outside the U.S.

The transaction is anticipated to impact Gilead's 2023 EPS by approximately $0.09-$0.11 per share, and legal counsel to Arcellx is provided by Wilson Sonsini Goodrich & Rosati.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!